Kamada (KMDA)

4.625
-0.045(-0.96%)
Pre Market
4.700
+0.075(+1.62%)
- Real-time Data
  • Volume:
    13,768
  • Day's Range:
    4.600 - 4.690
  • 52 wk Range:
    4.480 - 6.960

KMDA Overview

Prev. Close
4.67
Day's Range
4.6-4.69
Revenue
-
Open
4.667
52 wk Range
4.48-6.96
EPS
-
Volume
13,768
Market Cap
209.27M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
20,955
P/E Ratio
11.89
Beta
-
1-Year Change
-23.43%
Shares Outstanding
44,800,504
Next Earnings Date
Aug 09, 2022
What is your sentiment on Kamada?
or
Market is currently closed. Voting is open during market hours.

Kamada News

  • Stocks to watch next week
    • BySeeking Alpha-

    Key events are scheduled for the companies listed below next week. Notable earnings reports: Tyson Foods (NYSE:TSN), Progressive (NYSE:PGR), and Kamada (NASDAQ:KMDA) on...

  • Stocks to watch next week
    • BySeeking Alpha-

    Key events are scheduled for the companies listed below next week. Notable earnings reports: Hasbro (NASDAQ:HAS), Kimberly-Clark (NYSE:KMB) on October 23; McDonald's (NYSE:MCD),...

  • Kamada announces CFO transition
    • BySeeking Alpha-

    Kamada (NASDAQ:KMDA) announces that Gil Efron, Deputy CEO & CFO, will leave the Company at the end of the year. Chaime Orlev, will succeed him as CFO, effective January 1,...

Kamada Analysis

Kamada Company Profile

Kamada Company Profile

Employees
355
Market
Israel

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • MERCATOR  WA [MRCP] The leader in Europe with no debt and with ridiculous low PE about 4 after Q4 2020 report
    0
    • FDA APPROVAL SEASON: COVID-19 VERSION LIMITED ESITIONAfter Gilead’s approval, Surely there’ll be a wave of approvals in the vaccine related companies.
      0
      • There we go! 😍
        0
        • There are very big hopes here, treatment for Covid already working! question of time for 300% up!
          0
          • Go home to sleep
            2
        • down, down, down
          1
          • all over the world, shares will be falling
            0
            • boom tomorrow to the moon's 100$!!
              2
              • I saw the news but is it going to happen for sure? Are you experienced?
                1
              • Mohammad Alazzah sell on news
                1
              • Buy thr rumor and sell the news makes sense. Thanks
                0
            • daytrippers cause revenue harvest now but Kamd has stronger future
              0
              • why is it falling?
                0
                • One person was dead after treatment, but reason of the death not approved yet.
                  0
              • They should be releasing a test soon
                0